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AbstrAct
Objective
To determine if genetically increased serum calcium 
levels are associated with improved bone mineral 
density and a reduction in osteoporotic fractures.
Design
Mendelian randomisation study.
setting
Cohorts used included: the UK Biobank cohort, 
providing genotypic and estimated bone mineral 
density data; 25 cohorts from UK, USA, Europe, and 
China, providing genotypic and fracture data; and 17 
cohorts from Europe, providing genotypic and serum 
calcium data (summary level statistics).
ParticiPants
A genome-wide association meta-analysis of serum 
calcium levels in up to 61 079 individuals was used 
to identify genetic determinants of serum calcium 
levels. The UK Biobank study was used to assess the 
association of genetic predisposition to increased 
serum calcium with estimated bone mineral density 
derived from heel ultrasound in 426 824 individuals 
who had, on average, calcium levels in the normal 
range. A fracture genome-wide association meta-
analysis comprising 24 cohorts and the UK Biobank 
including a total of 76 549 cases and 470 164 
controls, who, on average, also had calcium levels in 
the normal range was then performed.
results
A standard deviation increase in genetically derived 
serum calcium (0.13 mmol/L or 0.51 mg/dL) was not 
associated with increased estimated bone mineral 
density (0.003 g/cm2, 95% confidence interval 
−0.059 to 0.066; P=0.92) or a reduced risk of 
fractures (odds ratio 1.01, 95% confidence interval 
0.89 to 1.15; P=0.85) in inverse-variance weighted 
mendelian randomisation analyses. Sensitivity 
analyses did not provide evidence of pleiotropic 
effects.
cOnclusiOns
Genetic predisposition to increased serum calcium 
levels in individuals with normal calcium levels is 
not associated with an increase in estimated bone 
mineral density and does not provide clinically 
relevant protection against fracture. Whether such 
predisposition mimics the effect of short term calcium 
supplementation is not known. Given that the same 
genetically derived increase in serum calcium is 
associated with an increased risk of coronary artery 
disease, widespread calcium supplementation in 
the general population could provide more risk than 
benefit.
Introduction
Fragility fractures are a large problem worldwide in 
both women and men, with an impact on quality 
of life and mortality.1 2 Calcium supplementation 
is promoted and emphasised by prevention and 
treatment guidelines to reduce the risk of osteoporosis 
and fractures,3-5 and is now common among the 
general adult population in high income countries.6-8 
For example, in the NHANES study, 53% of Americans 
used dietary calcium supplements and 43% reported 
daily use.9
Evidence, however, from multiple studies indica-
tes that increased serum calcium, a short term 
consequence of calcium supplementation, is associated 
with an increased risk of cardiovascular disease and 
mortality.10 11 A meta-analysis of serum calcium on 
incident risk of cardiovascular disease indicated that 
serum calcium was associated with an increased risk 
of cardiovascular disease.12 Higher circulating calcium 
levels have also been found to be associated with an 
increased risk of stroke in observational studies.13 14
However, observational associations of serum 
calcium with cardiovascular disease can be susceptible 
to confounding, even after controlling for known risk 
factors of the disease. Consequently, randomised 
controlled trials of calcium supplement use were 
undertaken because the process of randomisation 
breaks the association with confounding variables. 
Although these randomised controlled trials did 
not prespecify cardiovascular disease as a primary 
outcome, several meta-analyses have provided 
conflicting evidence, and most of these studies relied 
on short term calcium supplementation.10 15-19
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WhAt Is AlreAdy knoWn on thIs topIc
Calcium supplementation in the general population is common and often 
intended to reduce the risk of fracture
Calcium supplementation has been associated with an increased risk of coronary 
artery disease and its protective effects on bone health remain unclear
WhAt thIs study Adds
Genetic predisposition to increased serum calcium levels in individuals with 
normal calcium levels is not associated with an increase in estimated bone 
mineral density and does not provide clinically relevant protection against 
fracture
Given that the same genetically derived increase in serum calcium is associated 
with an increased risk of coronary artery disease, widespread calcium 
supplementation in the general population might provide more risk than benefit
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Another way to overcome confounding is by 
mendelian randomisation. Mendelian randomisation 
is an established genetic epidemiology method that 
uses natural genetic variation to strengthen causal 
inference by mimicking a lifelong randomised 
controlled trial.20 Specifically, genetic variants are 
identified that are reproducibly associated with the 
risk factor and are then tested for their combined effect 
on the disease outcome. Since genetic variants are 
randomly assigned at conception, this method greatly 
decreases confounding. Further, since conception 
always precedes disease onset, such studies are not 
prone to reverse causation. Mendelian randomisation 
studies are less prone to regression dilution bias than 
observational studies because genotypes are measured 
with a high degree of precision. Lastly, mendelian 
randomisation provides an estimate of lifelong 
exposure. Nonetheless, mendelian randomisation stu-
dies are limited by potential bias owing to horizontal 
pleiotropy, where the genetic variant influences the 
outcome, independently of the exposure, among other 
limitations.21
Our recent mendelian randomisation study found 
that lifelong genetically predicted increased serum 
calcium levels were associated with a higher risk of 
coronary artery disease and myocardial infarction,22 
such that a one standard deviation increase in serum 
calcium (0.13 mmol/L or 0.51 mg/dL) was associated 
with an increased odds of coronary artery disease 
(odds ratio 1.25, 95% confidence interval 1.08 to 1.45, 
P=0.003), comparable with previous randomised 
controlled trial meta-analysis estimations.12 Thus, 
given the risks of increased serum calcium and the 
high prevalence of calcium supplementation, it is 
important to understand the potential beneficial 
effects of calcium on skeletal health and fracture so 
that patients and their doctors can balance potential 
risks against potential benefits.
Clearly calcium is required for normal skeletal 
development and maintenance since net calcium 
excretion must be replaced.5 Indeed, severe hypo-
calcemia due to deficient calcium or vitamin D intake, 
or both, leads to diminished bone density and increased 
risk of fracture, which is improved with increased 
calcium intake.23-32 Yet, what remains unclear is 
whether additional calcium supplementation to an 
ordinary diet can lead to clinically relevant improve-
ments in heel ultrasound bone mineral density and 
prevent fractures in the general adult population, 
who in general, have normal serum calcium and 
parathyroid hormone levels. Randomised controlled 
trial data supporting calcium supplementation to 
prevent fractures is inconsistent and even large trials, 
such as the Women’s Health Initiative, have not shown 
any reduction in the risk of fracture with calcium plus 
vitamin D in community dwelling older women and 
men.33-38 Calcium supplementation alone might even 
increase the risk of hip fracture, the most devastating 
type of fragility fracture.38 39 Further, a recent 
randomised controlled trial using bisphosphonates 
to prevent bone fractures found profound beneficial 
effects without calcium supplementation,40 a result 
also supported by another randomised controlled trial 
with bone mineral density as an outcome.41
Given the potential risks of calcium supplements 
and their widespread use, it is important to understand 
if increasing calcium results in a reduced risk of 
osteoporosis and fracture. We therefore assessed 
whether genetically predicted lifelong higher serum 
calcium levels were associated with bone mineral 
density and the risk of fracture by using mendelian 
randomisation. To do so, we identified the genetic 
determinants of serum calcium levels in 61 079 
individuals and tested their effect on estimated bone 
mineral density (n=426 824) and the risk of fracture 
(76 549 cases and 470 164 controls).
Methods
study design and data sources
Selection of instrumental variables
Figure 1 shows that the causal interpretation of 
mendelian randomisation estimates relies on three 
assumptions. Firstly, the genetic variants, termed 
single nucleotide polymorphisms, must be associated 
with the risk factor of interest. Secondly, the genetic 
variant must not be associated with confounders 
(common causes of the risk factor and outcome 
association), which are not in the causal pathway 
between the risk factor and the outcome. Thirdly, 
the genetic variant is independent of the outcome 
conditional on the risk factor and confounders (that is, 
absence of horizontal pleiotropy). This means that the 
genetic variant’s effect on the outcome should only be 
mediated by the risk factor and, thus, not have a direct 
effect on the outcome independent of the risk factor. 
We undertook a two sample mendelian randomisation 
approach to test the effect of increased serum calcium 
on bone mineral density and fracture.42 Two sample 
mendelian randomisation identifies genetic variants to 
be associated with the exposure in one dataset and then 
tests the association of these variants with the outcome 
in a separate dataset. The advantage of this approach 
is that it allows for larger sample sizes, providing 
more precise estimates of effect of the exposure on the 
outcome. For an overview of the concepts and methods 
deployed in mendelian randomisation studies, we 
refer interested readers to a recent review by Holmes 
and colleagues.43
associations between single nucleotide 
polymorphisms and serum calcium concentration
We obtained seven single nucleotide polymorphisms 
associated with total serum calcium concentrations 
at a genome-wide significant level of P<5x10−8 from 
the largest serum calcium genome-wide association 
study meta-analysis to date.44 Genome-wide signifi-
cant associations between the single nucleotide 
polymorphism and serum calcium comply with the 
first assumption of mendelian randomisation (that 
is, association between instrument and exposure). 
The study consisted of a discovery cohort of 39 400 
individuals of European descent from 17 population 
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based studies. Serum calcium concentrations were 
quantified by colorimetric assay in most cohorts. 
Discovery analysis identified 14 genome-wide 
significant single nucleotide polymorphisms associa-
ted to serum calcium concentration, of which seven 
were replicated in a subsequent replication cohort 
of 21 676 individuals of European descent. The 
replicated single nucleotide polymorphisms were 
rs1801725 in CASR, rs1550532 in DGKD, rs780094 in 
GCKR, rs7336933 near VWA8 and DGKH, rs10491003 
near GATA3, rs7481584 in CARS, and rs1570669 near 
CYP24A1 (table 1). In addition to the seven replicated 
single nucleotide polymorphisms, we included a 
genetic variant, rs17711722: VKORC1L1 locus, which 
failed replication as defined by O’Seaghdha and 
colleagues (P>0.05 for replication),44 although the 
single nucleotide polymorphism remained genome-
wide significant after meta-analysis of their discovery 
and replication results. In addition, rs17711722: 
VKORC1L1 locus displayed functional plausibility 
given that it encodes an enzyme involved in vitamin 
K physiology, which is associated with calcium 
homeostasis.45 46
Bone mineral density and fracture genome-wide 
association study
Bone mineral density is a clinically relevant 
measure used to diagnose osteoporosis and to risk-
stratify for fracture. Estimated bone mineral density is 
derived from two heel ultrasound measures, velocity 
of sound, and broadband ultrasound attenuation, 
which is highly heritable (50% to 80%),47 and is a 
strong predictor of risk of fracture.48 49 To estimate 
the effect of serum calcium level on estimated bone 
mineral density and fracture we obtained summary 
statistics for the associations between the eight 
calcium modifying single nucleotide polymorphisms 
and estimated bone mineral density and fractures risk 
from our recent genome-wide association study on 
estimated bone mineral density consisting of 426 824 
white British individuals from the UK Biobank.50 In 
this well powered genome-wide association study, 518 
genome-wide significant loci accounted for 20% of the 
total variance in estimated bone mineral density, using 
13.7 million single nucleotide polymorphisms imputed 
to the Haplotype Reference Consortium panel.51
We performed an updated fracture fixed effect meta-
analysis comprising a total of 24 cohorts from two 
recently published fracture genome-wide association 
studies, which included 23 cohorts from Genetic 
Factors for Osteoporosis consortium (GEFOS), EPIC-
Norfolk study, and UK Biobank’s full release.50 52 The 
meta-analysis involved a total of 76 549 cases and 
470 164 controls (table 2). Fracture cases in GEFOS 
and EPIC-Norfolk cohorts included adults who had 
any fractures confirmed by medical, radiological, or 
questionnaires with the exclusion of skull, fingers, 
and toes as well as high trauma fractures, when 
available. The details of case ascertainment of each 
cohort were described previously.52 For UK Biobank, 
we included fracture cases reported from either 
hospital based fracture diagnosis according to ICD-10 
(international classification of diseases, 10th revision) 
codes, or questionnaire based self reported fracture. 
Fractures located at skull, face, hands and feet, 
pathological, and atypical fractures; periprosthetic 
fractures were excluded. Detailed description of 
fracture ascertainment in UK Biobank was described 
previously.50 Controls from all cohorts were defined as 
patients without a history of fracture. Approximately 
69.5% of all fracture cases and 78.1% of all samples in 
the 24 cohorts were from UK Biobank, whereas GEFOS 
Confounder
Mendelian randomisation assumptions
1. Genetic variants are associated with exposure (calcium levels)
2. Genetic variants are not associated with potential confounders
3. Genetic variants are not associated with outcome (eg, fracture),
     except through the exposure (such as a lack of horizontal pleiotropic
     effects)
Genetic variant Exposure Disease
Fig 1 | Mendelian randomisation assumptions
table 1 | summary statistics for calcium estimated bone mineral density (ebMD) and fracture for single nucleotide polymorphisms (snPs) influencing 
serum calcium
nearby 
gene chr
associated  
snP
calcium 
increasing 
allele
calcium serum gWas ebMD gWas * Fracture gWas 
allele 
freq
effect 
(mmol/l) P value
allele 
freq
effect 
(g/cm2) P value allele freq
Odds ratio 
(95% ci) P value
DGKD 2 rs1550532 C 0.32 0.0045 8x10−11 0.32 0.0022 0.50 0.32 1.004  (0.992 to 1.016) 0.51
CASR 3 rs1801725 T 0.15 0.0178 9x10−86 0.13 0.0046 0.077 0.13 0.993  (0.976 to 1.011) 0.45
GATA3 10 rs10491003 T 0.09 0.0068 5x10−9 0.09 −0.0002 0.77 0.09 1.013 (0.993 to 1.034) 0.21
CARS 11 rs7481584 G 0.72 0.0045 1x10−10 0.72 −0.0067 0.001 0.71 1.003 (0.990 to 1.016) 0.62
DGKH, VWA8 13 rs7336933 G 0.85 0.0055 9x10−10 0.85 0.00098 0.83 0.85 1.018  (1.000 to 1.033) 0.05
CYP24A1 20 rs1570669 G 0.34 0.0045 9x10−12 0.34 −0.0045 0.016 0.34 0.993  (0.981 to 1.005) 0.25
VKORC1L1 7 rs17711722 T 0.47 0.00375 8x10−9 0.44 0.0043 0.0180 0.45 0.998  (0.986 to 1.010) 0.68
*Mean (SD) eBMD is 0.54 g/cm2 (0.12 g/cm2)
GWAS=genome-wide association study
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table 2 | cohort descriptions
source study design
country of 
origin ethnicity
Mean 
(sD) age study type assessment method Fracture non-fracture total
estimated bone mineral density cohort
UK Biobank Cohort UK Mixed (white  
British subset 
used for analysis)
56.6 
(8.1)
Cohort Heel quantitative  
ultrasound (heel BMD)
NA NA 426 824
Fracture cohort
Age, Gene/Environment 
Susceptibility Reykjavik 
Study
Cohort Iceland Northern  
European
76.4 
(5.5)
Population 
based
Medical and  
radiographic records
1458 1727 3185
Anglo-Australasian 
Osteoporosis Genetics 
Consortium
Population cohort, 
and case control 
for fracture cases
Australia North western 
European
69.6 
(8.6)
Population 
based, clinical 
based
Questionnaire,  
radiography
685 1113 1798
B-vitamins for the  
PRevention Of  
Osteoporotic Fractures
Intervention  
study
Netherlands North western 
European
74.3 
(6.5)
General popu-
lation
History of fractures before 
baseline: questionnaire. 
Incident fractures: self report, 
validated at GP or hospital
715 1483 2198
Cardiovascular Health 
Study
Cohort US European  
American
73.2 
(5.9)
Population 
based
Self report of incident  
fracture of the hip, leg,  
arm, or vertebra
519 2742 3261
DeCODE Genetics Study Cross sectional Iceland North western 
European
60.7 
(13.9)
Population 
based, clinical 
based
Medical records,  
radiographic documentation,  
questionnaire
1836 14 560 16 396
Estonian Genome Center 
University of Tartu-I
Cohort Estonia Northern  
European
55.4 
(20.2)
Population 
based
Medical records,  
questionnaire
217 4296 4513
Estonian Genome Center 
University of Tartu-II
Cohort Estonia Northern  
European
40.3 
(16.1)
Population 
based
Medical records,  
questionnaire
71 1717 1788
Erasmus Rucphen  
Family
Cohort Netherlands North western 
European
48.8 
(14.6)
Family based 
isolate
Interview 260 1342 1602
Framingham Heart  
Study
Cohort US European  
American
64.7 
(11.2)
Population and 
family based
Medical records,  
questionnaire
1520 2782 4302
Gothenburg Osteoporosis 
and Obesity Determinants 
Study
Cohort Sweden Northern  
European
18.9 
(0.6)
Population 
based
Radiographic  
document
273 597 870
Health Aging and Body 
Composition
Cohort US European  
American
73.8 
(2.9)
Population 
based
Radiographic 308 1353 1661
Hong Kong Southern 
Chinese
Case control China Southern  
Chinese
48.9 
(15.6)
Population 
based, clinic 
based
Medical records,  
radiographic, and 
questionnaire
79 627 706
MrOS Cohort US European  
American
73.9 
(5.9)
Clinic based Questionnaire, radiographic 
documentation
918 3555 4473
The PROpective Study of 
Pravastatin in the Elderly 
at Risk
Cohort,  
randomised  
controlled trial
Netherlands,  
UK, Ireland
North western 
European
75.4 
(3.4)
Clinic based Medical records 426 4816 5242
Rotterdam Study I Cohort Netherlands North western 
European
69.4 
(9.0)
Population 
based
Medical records,  
questionnaire
2163 3574 5737
Rotterdam Study II Cohort Netherlands North western 
European
63.8 
(7.1)
Population 
based
Medical records,  
questionnaire
932 1220 2152
Rotterdam Study III Cohort Netherlands North western 
European
56.1 
(5.4)
Population 
based
Medical records,  
questionnaire
505 2421 2926
Study of Osteoporotic 
Fractures
Cohort US European  
American
71.5 
(5.2)
Clinic based Questionnaire,  
radiographic  
documentation
1611 1698 3309
TwinsUK Cohort UK North western 
European
49.9 
(13.6)
Population 
based, family 
based
Medical records,  
radiographic, and  
questionnaire
839 4111 4950
Women’s Genome Health 
Study
Cohort US European  
American
54.1 
(7.1)
Population 
based
Questionnaire 1832 20 498 22 330
Women’s Health  
Initiative Clinical Trial
Quasi  
case/control
US European  
American
69.0 
(6.4)
Population 
based
Medical records 1058 647 1705
Women’s Health Initiative 
Observational Study
Quasi  
case/control
US European  
American
69.0 
(6.5)
Population 
based
Medical records 1603 989 2592
CV risk in Young Finns 
Study
Cohort Finland Northern  
European
38.0 
(5.0)
Population 
based
Medical records 611 975 1586
European Prospective  
Investigation into  
Cancer, Norfolk study
Cohort UK North western 
European
59.1 
(9.3)
Population 
based
Medical records 2926 17 710 20 636
UK Biobank Cohort UK Mixed (white  
British subset 
used for analysis)
56.8 
(8.0)
Cohort Questionnaire, based on 
answering yes to the question 
“Have you fractured/broken 
any bones in the last 5 
years?” at either baseline or 
first follow up
53 184 373 611 426 795
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cohorts represented 26.7% of cases and 18.2% of all 
samples and EPIC-Norfolk provided 2.8% of all cases 
and 3.8% of all samples. Table 2 shows the mean age 
of the GEFOS and EPIC-Norfolk cohorts.
Linear regression involving UK Biobank’s fracture 
cohort was performed using BOLT-LMM,53 an algorithm 
that allows for large scale mixed model association 
testing. Our genome-wide association study analysis 
included adjustment for sex, age, assessment centre, 
genotyping array, and first 20 principle components. 
Before meta-analysis with GEFOS and EPIC-Norfolk, 
and owing to the use of BOLT-LMM,53 54 the effect 
size estimate and standard error of each genetic 
variant (single nucleotide polymorphism) from UK 
Biobank’s genome-wide association study analysis 
was transformed to odds ratios by using the following 
approximation: log odds ratio=β/(μ*(1−μ)), where μ is 
the case fraction in UK Biobank’s fracture cohort.52
The UK Biobank full release fracture genome-wide 
association study was performed on its white British 
subpopulation, which included 53 184 fracture cases 
and 373 611 controls. The mean age of the UK Biobank 
fracture cohort is 56.8±8.0 (table 2). The study 
cohorts involved in the serum calcium genome-wide 
association study were mostly of European descent.44 
The estimated bone mineral density genome-wide 
association study cohort consisted of all white 
British patients from the UK.55 Fracture cohorts were 
predominantly of European descent: Europe (91.6%), 
North America (8.0%), Australia (0.3%), and East Asia 
(0.1%).50
We used METAL to perform fixed effects meta-
analysis of these results. Individual genome-wide 
association studies were corrected by genomic 
control,56 and a total of 8 818 767 autosomal single 
nucleotide polymorphisms were included in the 
meta-analysis. The average genomic inflation λ of 
24 cohorts was 1.025 and was adjusted accordingly 
when performing the meta-analysis. Finally, summary 
statistics from the eight calcium associated single 
nucleotide polymorphisms (table 1) were extracted 
from the fracture meta-analysis described above.
single nucleotide polymorphism validation and 
pleiotropy assessment
We next undertook sensitivity analysis to understand 
if any of the single nucleotide polymorphisms might 
violate assumptions of mendelian randomisation.
Linkage disequilibrium
Single nucleotide polymorphisms used for mendelian 
randomization analysis are assumed to be independent 
of each other.21 Given that the eight identified 
calcium associated single nucleotide polymorphisms 
are located on different chromosomes, they would 
segregate independently of each other and, hence, are 
not in linkage disequilibrium.
Pleiotropy
To avoid a biased estimation of the effect of serum calcium 
(risk factor) on either the risk of estimated bone mineral 
density or fracture (outcomes), the genetic variants 
(instruments) used in the mendelian randomisation 
analysis should only affect the outcome only through 
serum calcium. Thus, we evaluated potential 
associations of our selected calcium associated single 
nucleotide polymorphisms with known determinants 
of bone mineral density and fracture by searching 
the selected single nucleotide polymorphisms in 
Phenoscanner, a database of genome-wide association 
study results.57 We further assessed whether each of the 
eight single nucleotide polymorphisms were expression 
quantitative trait loci for genes that could be associated 
with known determinants of bone mineral density and 
fracture by using the GTEX database.50 58 Although 
direct pleiotropic effects that influence the outcome 
independently of the risk factor violate mendelian 
randomisation assumptions (red arrow in fig 1), vertical 
pleiotropy does not. Vertical pleiotropy is defined as 
the association of a single nucleotide polymorphism 
with more than one phenotype in the same biological 
pathway.43 For example, genetically lowered calcium at 
CASR could lead to increased parathyroid hormone,59 
which itself might influence bone mineral density 
and fracture. But since calcium directly influences 
parathyroid hormone, which influences the outcome, 
this is not a violation of mendelian randomisation 
assumptions.
comparison of genetically derived effects with 
pharmacological effects of calcium supplementation
We modelled the effect of a one standard deviation 
genetically derived increase in serum calcium on 
estimated bone mineral density and fracture. We 
compared this one standard deviation increase with 
the magnitude of increase in serum calcium levels after 
calcium supplementation. To do so, we compared data 
from a recent randomized crossover trial of calcium 
supplementation.60
Mendelian randomisation
Individual mendelian randomisation estimates from 
the seven independent serum calcium associated 
single nucleotide polymorphisms were calculated by 
using the Wald method.61 We meta-analysed individual 
mendelian randomisation estimates by using both 
inverse-variance weighted and a random effects models 
using R and the package MendelianRandomization and 
RStudio.62-64 The estimated associations of genetically 
predicted serum calcium with estimated bone mineral 
density and odds of fracture were expressed with 
respect to one standard deviation increase in serum 
calcium levels, which is equivalent to 0.51 mg/dL or 
0.13 mmol/L. This standard deviation equivalence 
was derived from serum calcium’s pooled variance 
calculation involving the 30 cohorts reported in 
O’Seaghdha and colleagues and included in the serum 
calcium genome-wide association study.44
sensitivity analyses
To explore potential pleiotropic effects, we carried 
out three sensitivity meta-analyses: simple and 
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weighted median and mendelian-randomisation-
Egger regression methods using the R package 
MendelianRandomization.63 Simple and weighted 
median meta-analyses provide estimations that 
are robust to the inclusion of up to 50% invalid 
instruments in a mendelian randomisation analy-
sis.65 The intercept estimate from mendelian-
randomisation-Egger regression analysis provides a 
useful estimation of directional horizontal pleiotropy, 
that is, the magnitude and direction of the effect of the 
single nucleotide polymorphisms on the outcome not 
mediated through the exposure.66
In addition to the primary analysis, we performed 
two additional sensitivity analyses. Firstly, we repeated 
our analysis including rs17711722 near VKORC1L1. 
rs17711722 is associated with serum calcium levels at 
a genome-wide significant level, but it was not included 
in the main findings because it did not meet replication 
criteria.44 Lastly, we performed an additional analysis 
by excluding rs1801725 (CASR), which contributed the 
most weight in the inverse-variance weighted primary 
meta-analysis (CASR single nucleotide polymorphism 
explained 0.49% of the serum calcium variance). This 
single nucleotide polymorphism is in LD with single 
nucleotide polymorphism rs73186030, which has 
been associated with parathyroid hormone levels.59 
The rationale was to test whether, in its absence, the 
estimated calcium on bone mineral density and on 
fracture effects were similar to those from primary 
analyses or if they were mostly driven by CASR.
In addition, to assess whether Asian ancestry 
influenced our fracture mendelian randomisation 
results, we performed the fracture genome-wide 
association study meta-analysis removing the HKOS 
(Southern Chinese) cohort and repeated the fracture 
mendelian randomisation.
Patient and public involvement
No patients or member of the general public were 
directly involved in the design, recruitment, or 
conduct of the study. After publication, dissemination 
of the results will be sought across different countries 
involving respective patient organisations, the general 
public, and other stakeholders; typically, across social 
media, scientific meetings, and media interviews.
results
single nucleotide polymorphism selection
Table 1 shows that the single nucleotide polymorphisms 
in eight loci previously identified to be associated with 
serum calcium were rs1801725 in CASR (P=9x10−86), 
rs1550532 in DGKD (P=8x10−11), rs780094 in GCKR 
(P=1x10−10), rs7336933 near VWA8 and DGKH 
(P=9x10−10), rs10491003 nearby GATA3 (P=5x10−9), 
rs7481584 in CARS (P=1x10−10), rs1570669 near 
CYP24A1 (P=9x10−12), and rs17711722 near 
VKORC1L1 (P=8x10−9). The selected single nucleotide 
polymorphisms collectively explained 0.77% of 
the variance in total serum calcium levels, which 
is sufficient to influence the risk of coronary artery 
disease.22
Known biology at associated loci
Among these single nucleotide polymorphisms, 
rs1801725 (CASR) and rs1570669 (CYP24A1) are 
located nearby genes whose functions are involved in 
calcium homeostasis.22 The most strongly associated 
calcium locus includes CASR, a calcium sensing 
receptor. CASR encodes a protein whose main 
function is to capture small changes in circulating 
calcium concentrations and consequently modify 
parathyroid hormone secretion and renal cation 
handling.67CYP24A1 encodes an enzyme that plays a 
role in calcium homeostasis and the metabolism of the 
active form of vitamin D.68 The diacylglycerol kinase 
genes DGKD and DGKH genes have recently been 
implicated in calcium signaling.69GATA3 and the CARS 
locus are reportedly associated with hypocalcemia in 
the hypoparathyroidism, sensorineural deafness, and 
renal dysplasia (hypoparathyroidism, deafness, and 
renal dysplasia syndrome) and Beckwith-Wiedemann 
syndromes, respectively.70 The remaining single 
nucleotide polymorphism, rs17711722, used for 
sensitivity analysis is located in VKORC1L1, is also 
associated with calcium homeostasis.45 Thus, all loci 
associated with calcium levels contained genes with 
plausible biological effects on calcium levels.
Pleiotropy evaluation
Single nucleotide polymorphisms rs1801725 in CASR, 
rs7336933 near VWA8 and DGKH, rs10491003 nearby 
GATA3, rs7481584 in CARS, and rs1570669 near 
CYP24A1 were not associated with any phenotypes 
other than serum calcium in the Phenoscanner and 
MRBase databases. Besides its association with 
calcium levels, rs1550532 in DGKD showed evidence 
of association with bilirubin levels.71-73 Bilirubin, 
however, is not associated with bone mineral density 
or with fracture.74 Single nucleotide polymorphism 
rs17711722 (VKORC1L1) showed genome-wide level 
associations with corneal structure and central corneal 
thickness,75 yet these phenotypes are not known to be 
related to a calcium-independent effect on estimated 
bone mineral density and fracture. Single nucleotide 
polymorphism rs780094 in GCKR had genome-
wide level associations with triglycerides levels, 
cholesterol, waist circumference, and several other 
lipid-related phenotypes.73 76-78 Waist circumference 
is highly associated with weight and BMI, which 
are known determinants of lower extremity bone 
density and potentially heel bone mineral density.79 
Thus, the highly pleiotropic nature of rs780094 in 
GCKR represents a calcium-independent effect on 
our outcomes of interest and was removed from all 
subsequent analyses.
association of calcium levels modifying single 
nucleotide polymorphisms with estimated risk of 
bone mineral density and fracture 
Table 1 shows that the summary statistics for the 
association between seven calcium increasing single 
nucleotide polymorphisms and estimated bone 
mineral density and fracture odds were directly 
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obtained without the use of proxy single nucleotide 
polymorphisms from their respective studies.55 None 
of the seven calcium single nucleotide polymorphisms 
had genome-wide significant associations with either 
estimated bone mineral density or odds of fracture (all 
P>0.08).
comparison of genetically derived effects with 
pharmacological effects of calcium supplementation
A previous crossover randomised controlled trial 
showed that 500 mg of calcium citrate in a fasting 
state lead to a maximal increase in total serum calcium 
levels by approximately 0.07 mmol/L, four hours 
after administration.60 The mendelian randomisation 
analyses here represent a change in total serum 
calcium of one standard deviation, which is 0.13 
mmol/L. Therefore, the effects of total serum calcium 
presented include the anticipated effects of calcium 
supplementation.
Mendelian randomisation analysis: serum calcium 
on estimated bone mineral density
Table 3 and figure 2 show that when performing 
mendelian randomisation analyses, a one standard 
deviation (that is, 0.51 mg/dL or 0.13 mmol/L) increase 
in serum calcium concentration was not associated with 
a clinically relevant change in estimated bone mineral 
density (change per standard deviation increase in 
serum calcium 0.003 g/cm2, 95% confidence interval 
−0.059 to 0.066; P=0.92). The mean and standard 
deviation of estimated bone mineral density are 0.54 
g/cm2 and 0.12 g/cm2, respectively.
Figure 2 lists the individual level randomisation 
estimates of the single nucleotide polymorphisms 
used in the inverse variance weighted analysis. 
Mendelian randomisation estimates as determined 
by rs7481584 (CARS −0.19 g/cm2, 95% confidence 
interval −0.30 to −0.08; P=0.001) and rs1570669 
(CYP24A1 −0.13 g/cm2, −0.24 to −0.02; P=0.02) 
showed a statistically significant decrease in estimated 
bone mineral density per standard deviation increase 
in serum calcium. However, only the former remained 
statistically significant after Bonferroni correction for 
multiple hypothesis testing involving six tests, that is, 
0.05/6=8.3 x 10-3. Mendelian randomisation estimates 
as determined by the remaining single nucleotide 
polymorphisms showed a lack of association between 
a standard deviation increase in serum calcium and 
estimated bone mineral density.
Table 3 shows that the sensitivity meta-analyses with 
six single nucleotide polymorphisms involving simple 
median (0.009 g/cm2, 95% confidence interval −0.052 
to 0.070; P=0.76) and weighted median estimation 
(0.030 g/cm2, −0.006 to 0.067; P=0.10) supported 
the inverse-variance weighted primary analysis. The 
mendelian-randomisation-Egger regression intercept, 
which provides an approximate estimation of 
directional pleiotropic effects on estimated bone 
mineral density through pathways independent of 
serum calcium, showed no significant evidence for 
such effects (−0.003 g/cm2, −0.006 to 0.001; P=0.11).
Table 3 shows that the inclusion of an additional 
serum calcium increasing single nucleotide polymor-
phism (rs17711722, VKORC1L1) to the primary 
analysis also indicated that a one standard deviation 
increase in serum calcium was not associated with 
clinically relevant change in estimated bone mineral 
density of 0.011 g/cm2 (95% confidence interval 
−0.050 to 0.073; P=0.72).
To assess the degree to which our primary 
mendelian randomisation inverse-variance weighted 
estimate would change by removing the single 
nucleotide polymorphism that provided most weight 
to the inverse-variance weighted analysis, we ran an 
additional sensitivity analysis excluding rs1801725 
(CASR). Results were, as expected, less precise but did 
not differ materially from the results of the primary 
analyses (eg, inverse-variance weighted estimate 
−0.049 g/cm2, 95% confidence interval −0.144 to 
0.047; P=0.32; table 3).
Mendelian randomisation analysis: serum calcium 
association with fracture
We estimated the effect of a genetically average 
increased serum calcium on odds of fracture by 
implementing a random effects model and inverse-
variance weighted method, which included six 
calcium-increasing alleles described in table 1. Figure 
3 and table 3 show that a one standard deviation 
increase in serum calcium concentration was not 
associated with odds of fracture (odds ratio 1.01, 95% 
confidence interval 0.89 to 1.15; P=0.85).
table 3 | Mendelian randomisation results for effect of serum calcium on estimated bone mineral density (ebMD) and fracture risk
Method
Main analysis sensitivity analyses
6 serum calcium associated snPs including rs17711722 (vKOrc1l1) excluding rs1801725 (casr)
Mean ebMD  
(95% ci)
P  
value
Fracture odds 
ratio (95% ci)
P  
value
Mean ebMD  
(95% ci)
P  
value
Fracture odds 
ratio (95% ci)
P  
value Mean ebMD
P  
value
Fracture odds 
ratio (95% ci)
P  
value
IVW 0.003  (−0.059 to 0.066) 0.92−
1.01  
(0.89 to 1.15) 0.85
0.011  
(−0.05 to 0.073) 0.72−
1.01  
(0.90 to 1.13) 0.91
−0.049  
(−0.144 to 0.047) 0.32−
1.12  
(0.92 to 1.36) 0.25
Simple  
median
0.009  
(−0.052 to 0.070) −0.76
1.11  
(0.93 to 1.33) 0.24
0.023  
(−0.035 to 0.081) 0.44−
1.10  
(0.91 to 1.32) 0.32
−0.004  
(−0.093 to 0.085) 0.93−
1.13  
(0.89 to 1.42) 0.32
Weighted 
median
0.030  
(−0.006 to 0.067) −0.10
0.99  
(0.89 to 1.11) 0.91
0.031  
(−0.005 to 0.068) 0.09−
0.98  
(0.88 to 1.10) 0.76
−0.009  
(−0.093 to 0.076) 0.84−
1.12  
(0.90 to 1.41) 0.31
MR-Egger 
intercept
−0.003  
(−0.006 to 0.001) −0.11
1.00  
(1.00 to 1.01) 0.39
−0.001  
(−0.005 to 0.002) 0.49−
1.00  
(1.00 to 1.01) 0.52
−0.005  
(−0.019 to 0.008) 0.45−
0.98  
(0.96 to 1.01) 0.14
Results are expressed per one standard deviation (0.51 mg/dL or 0.13 mmol/L) increase in serum calcium concentration. Estimated bone mineral density (eBMD) is expressed in g/cm2.
IVW=inverse-variance weighted meta-analysis
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Figure 3 shows the estimates from individual 
level single nucleotide polymorphism mendelian 
randomisation analysis. Mendelian randomisation 
estimates after Bonferroni correction for multiple 
hypothesis testing involving six tests did not show a 
change in odds of fracture per one standard deviation 
increase in serum calcium.
Table 3 shows that sensitivity meta-analyses with 
six single nucleotide polymorphisms involving simple 
median (odds ratio 1.11, 95% confidence interval 0.93 
to 1.33; P=0.24) and weighted median estimation 
(0.99, 0.89 to 1.11; P=0.91) supported inverse-
variance weighted primary analysis results. Mendelian-
randomisation-Egger intercept regression results 
(1.00, 1.00 to 1.01; P=0.39) provided no evidence of 
directional pleiotropic effects on fracture odds through 
pathways independent of serum calcium.
The inclusion of an additional serum calcium 
increasing single nucleotide polymorphism (rs1-
7711722, VKORC1L1) to our primary analysis with one 
standard deviation increase in serum calcium (inverse-
variance weighted odds ratio 1.01, 95% confidence 
interval 0.90 to 1.13; P=0.91).
We also assessed the degree to which our primary 
mendelian randomisation inverse-variance weighted 
estimate would change by removing the single 
nucleotide polymorphism that provided highest 
weight to the inverse-variance weighted analysis, that 
is, rs1801725 (CASR). Again, the results were less 
precise, but were not materially different from the 
primary inverse-variance weighted estimate (inverse-
variance weighted odds ratio 1.12, 95% confidence 
interval 0.92 to 1.36; P=0.25).
Finally, to assess whether the presence of a cohort 
of Asian ancestry (HKOS) in our fracture genome-wide 
association study could affect our fracture mendelian 
randomisation results, we performed the fracture 
genome-wide association study meta-analysis after 
removing the HKOS (Southern Chinese) cohort and 
repeated the fracture mendelian randomisation 
analysis. As observed in table 4 and figure 4, our 
instrumental variables’ summary statistics and mende-
lian randomisation results were virtually identical to 
those obtained in our primary analysis. The genomic 
inflation factor (λ) without and with the inclusion of 
HKOS cohort remained unchanged at 1.025. Therefore, 
inclusion of the HKOS cohort of Southern Chinese 
ancestry did not affect our results.
discussion
This mendelian randomisation study showed that a 
standard deviation increase in lifelong serum calcium 
levels was not associated with increased estimated 
bone mineral density or reduced risk of fracture in 
individuals with normal calcium levels. The magnitude 
of a one standard deviation increase in genetically 
predicted serum calcium includes the increase 
in serum calcium that would be anticipated after 
calcium supplementation.60 80 Assuming a linear effect 
between calcium levels and the studied outcomes, 
this suggests that widespread efforts to use calcium 
supplements in the general population for long periods 
of time are unlikely to have any substantial effect 
on bone health outcomes. Further, we have recently 
shown that genetically determined increase in serum 
calcium derived from the same instruments (that is, 
single nucleotide polymorphisms) is associated with 
a clinically relevant increase in the risk of coronary 
artery disease.22 Thus, the cardiovascular risks of 
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Fig 2 | serum calcium effects on estimated bone mineral density (ebMD). two sample 
mendelian randomisation: individual and inverse-variance weighted (ivW) results
table 4 | summary statistics for fracture single nucleotide polymorphisms (snPs) influencing serum calcium including 
and excluding HKOs cohort of asian descent
nearby gene chr
associated  
snP
calcium  
increasing  
allele
Fracture gWas Fracture gWas excluding HKOs cohort
allele 
freq
Odds ratio  
(95% ci) P value allele freq
Odds ratio  
(95% ci) P value
DGKD 2 rs1550532 C 0.32 1.004  (0.992 to 1.016) 0.51 0.32
1.004  
(0.992 to 1.017) 0.53
CASR 3 rs1801725 T 0.13 0.993  (0.976 to 1.011) 0.45 0.13
0.993  
(0.976 to 1.011) 0.44
GATA3 10 rs10491003 T 0.09 1.013  (0.993 to 1.034) 0.21 0.09
1.013  
(0.993 to 1.034) 0.21
CARS 11 rs7481584 G 0.71 1.003  (0.990 to 1.016) 0.62 0.71
1.004  
(0.991 to 1.017) 0.59
DGKH, VWA8 13 rs7336933 G 0.85 1.018  (1.000 to 1.033) 0.05 0.85
1.017  
(1.000 to 1.033) 0.05
CYP24A1 20 rs1570669 G 0.34 0.993  (0.981 to 1.005) 0.25 0.34
0.993  
(0.980 to 1.005) 0.24
VKORC1L1 7 rs17711722 T 0.45 0.998  (0.986 to 1.010) 0.68 0.45
0.998  
(0.986 to 1.010) 0.71
GWAS=genome-wide association study
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increasing serum calcium in the general population 
are unlikely to be offset by beneficial effects on bone 
density and fracture.
Calcium is vital to many biological processes, 
and its serum concentration is tightly regulated. Net 
calcium excretion must be replaced, but the amount 
of calcium needed is debated. What is not well 
understood is whether increases in serum calcium 
amongst individuals who have a normal varied diet 
and normal calcium levels lead to a decrease in the 
risk of fracture. As outlined above, there is conflicting 
observational epidemiological evidence that calcium 
supplementation does not reduce the risk of fracture, 
yet such studies could be prone to bias since the 
individuals most likely to use calcium supplements 
are those more likely to be at a higher risk of fracture.81 
The mendelian randomisation approach employed 
here overcomes this potential confounding by relying 
on the random assignment of alleles at conception, 
thereby preventing associations with such potentially 
confounding factors.
One way to improve the quality of evidence in 
medical research is to employ the principles of 
triangulation of different sources of evidence. If results 
are consistent across different types of study designs, 
and these different types of designs have different 
sources of potential bias, then the results can be 
combined in the framework of triangulation to provide 
a higher standard of evidence.82 83 Of importance, 
our recent mendelian randomisation analysis that 
instrumented lactase persistence in adults as a 
surrogate for consumption of calcium-bearing dairy 
products found evidence of no protective effect of 
sustained dairy intake on the risk of fracture,52  84 
which is supported by our present results. Further, 
our mendelian randomisation findings are consistent 
with those of the aforementioned observational 
studies, numerous randomised controlled trials, and 
randomised controlled trial meta-analysis.33-38
Strengths of this study include the large sample size 
for estimated bone mineral density and fracture.50 
52 Further, multiple sensitivity analyses, including 
removing the single nucleotide polymorphisms 
most strongly associated with calcium levels, led to 
similar findings. Despite multiple sensitivity analyses, 
we did not identify pleiotropic effects of the single 
nucleotide polymorphisms on the skeletal outcomes, 
independent of serum calcium, as a potential source 
of bias. Of relevance, the serum calcium genome-wide 
association study from where we obtained serum 
calcium instruments was composed of population 
based cohorts that, on average, are normocalcemic, 
thus our reference population is normocalcemic 
adults. Hence, our study conclusions are applicable 
to normocalcemic adult populations similar to those 
in the general population, not to subpopulations, for 
example, with extremely low calcium level, which 
could benefit from calcium supplementation.
limitations
These findings cannot provide insight into the effects 
of hypocalcemia and its correction on estimated 
bone mineral density and the risk of fractures. We 
have assumed a linear effect between calcium levels 
and the studied outcomes and tested these effects 
on individuals from the general population, who on 
average, have normal serum calcium levels. Thus, 
these findings can only provide insight into the 
effect of further increases in serum calcium levels 
in eucalcemic individuals. Most individuals studied 
for bone mineral density and fracture outcomes did 
not have osteoporosis as defined by bone mineral 
density measurement. Thus, the effects of genetically 
increased calcium in such individuals should be tested 
separately. 
Most randomised controlled trials for prevention of 
fracture have used calcium and vitamin D supplements 
in conjunction with fracture preventive therapies and 
it is not clear whether giving such drugs in the absence 
of calcium supplements would provide the same 
protective benefits as were shown in these randomised 
controlled trials. Nonetheless, many randomised 
controlled trials for fracture prevention have given 
calcium and vitamin D supplements in the control arm 
of the study. Further, a recent randomised controlled 
trial of zoledronate showed marked reductions in the 
risk of fracture without the use of calcium.40
Regarding study populations, there is no overlap 
between the fracture genome-wide association study 
and the estimated bone mineral density genome-wide 
association study. Fracture genome-wide association 
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Fig 3 | serum calcium effects on odds of fracture. two sample mendelian randomisation: 
individual and inverse variance weighted (ivW) results
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Fig 4 | serum calcium effects on odds of fracture excluding cohort with asian descent: 
sensitivity analysis. two sample mendelian randomisation: individual and inverse 
variance weighted (ivW) results
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study overlapped in a 2.8% with the calcium genome-
wide association study population. However, we do 
not expect a substantial impact given the low degree 
of overlap.85 Confounding by ancestry, also known 
as population stratification, can bias mendelian 
randomisation studies. A method to overcome such 
confounding is to limit the study to people of the same 
ancestry. Although most individuals in the fracture 
study were of European ancestry, ∼1% of individuals 
were of Asian descent. However, removal of this Asian 
cohort did not impact on our results. 
Our study provides insights into serum calcium 
levels and not tissue level concentrations. While 
these different compartments of calcium homeostasis 
might have different effects on the risk of fracture, 
calcium supplementation acts on the skeleton by first 
influencing serum calcium. Thus, the results presented 
here can provide insight into the expected effects of 
calcium supplementation by serum calcium. Further, 
the mendelian randomisation estimate for fracture, 
a binary outcome, was expressed as an odds ratio, 
which is a non-collapsible measure, yet this estimator 
still provides a valid test of the null hypothesis.86 
Canalization, which is the sum of compensatory 
feedback mechanisms returning a physiological system 
to homeostasis, can bias mendelian randomisation 
results towards the null. However, it is plausible the 
same mechanisms which maintain calcium homeostasis 
would act in a similar fashion on serum calcium raised 
by supplementation and by genetic effects. Further, 
the genetic predisposition to increased serum calcium 
used in our study is of sufficient biological and clinical 
relevance because of its association with increased risk 
of coronary artery disease.22
conclusions
A genetic predisposition to increased serum calcium, 
amongst individuals with normal calcium levels, 
was not associated with increased estimated bone 
mineral density or decreased risk of fracture. The 
degree to which lifelong genetically derived increased 
serum calcium mimics the effect of long term calcium 
supplementation is not known. Since genetically 
elevated serum calcium is strongly associated with an 
increased risk of coronary artery disease, widespread 
calcium supplementation in the general population 
does not appear to have a favourable risk-benefit 
profile.
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